The P-III trial (ADAURA) evaluating Tagrisso (80mg, qd) vs PBO in 682 patients with Stage IB, II, IIIA EGFRm NSCLC at 200+ centers across 20+ countries, incl. the US, EU, South America, Asia & the Middle East
The results showed a clinical improvement in OS. The safety & tolerability were consistent with its established profile with no new safety concerns & the results data will be presented at an upcoming medical meeting
Tagrisso was approved to treat early-stage lung cancer in 90+ countries, incl. in the US, EU, China, and Japan along with additional global regulatory reviews are ongoing. The company has a comprehensive portfolio of approved & potential new therapies for lung cancer
Ref: Astrazeneca | Image: Astrazenneca
Related News:- HUTCHMED and AstraZeneca Report P-II (SAVANNAH) Trial Results of Tagrisso + Savolitinib for EGFR-Mutated NSCLC
